Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P6 vs Herceptin in HER2-positive early breast cancer
NCT02162667Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Celltrion. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT02162667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162667.